Plain-English translation of NCT06195072 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing two investigational medications— and Nerandomilast (BI 1015550)—to see if they can slow or improve lung damage caused by systemic sclerosis, a disease where the body's connective tissue becomes thick and stiff. The study will compare how well each medication works compared to placebo (a dummy pill with no active ingredient) by measuring changes in lung function over one year in people with scleroderma-related lung disease.
Systemic sclerosis often damages the lungs in ways that get worse over time, causing breathing problems and disability. There are very few treatment options available, so researchers are testing whether these new medications might slow lung damage and help people breathe better.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic regularly over 52 weeks (about one year) to receive either one of the two test medications or a placebo pill—you won't know which one you're getting. You'll have lung function tests, chest CT scans, blood work, and physical exams to see how the medication is working and to watch for any side effects. The study involves about 400 participants across multiple centers.
AI-generated summary from trial data · Sep 5, 2026 · Not medical advice
United States